The European Medicines Agency said that there was no plan to change the product information at present, but the situation was under review.
In a statement, GlaxoSmithKline (GSK) said that patient safety was its top priority, and reports of side effects were constantly monitored.
The statement added that the drug had been extensively tested in clinical trials involving 30,000 patients.
"Alli is a 'non-systemically' acting medicine, it is minimally absorbed in the blood and works locally in the gastro-intestinal tract. There is therefore no obvious biological mechanism to suggest liver damage can occur with Alli," the BBC quoted the company as saying in the statement.
Source-ANI
ARU